Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 522 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Viread Clear all

Conditions: Chronic Hepatitis B
Interventions: RO7565020, Placebo, Nucleos(t)ide analogue (NUC) treatment; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Prevention
Interventions: Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen; Drug · Radiation
Lead sponsor: Ian McGowan; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Efavirenz, Lamivudine, Tenofovir DF; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Women's Health, HIV Infection, Genital Diseases, Female
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hepatitis B, Chronic
Interventions: Entecavir, Entecavir + Tenofovir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • San Jose, California + 10 more

Conditions: HIV
Interventions: Stribild, Atripla; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Tuberculosis
Interventions: rifapentine (M000473), EFZ EMT TDF; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more

Conditions: Hepatitis B
Interventions: JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer, HIV Prevention
Interventions: tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Herpes Simplex Type II
Interventions: TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: Dolutegravir, Atripla, Abacavir/Lamivudine, Abacavir/Lamivudine Placebo, Dolutegravir placebo, Atripla placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 844 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 55
States / cities: Hobson City, Alabama • Little Rock, Arkansas • Bakersfield, California + 42 more

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: HIV-1 Infection
Interventions: BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more

Conditions: Healthy Volunteer
Interventions: atazanavir, danoprevir, ritonavir, tenofovir disoproxil fumarate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Tuberculosis, Hiv
Interventions: Rifapentine daily, Rifapentine weekly; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 34
States / cities: Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more

Conditions: Human Immunodeficiency Virus
Interventions: Dolutegravir 50 MG, Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stimulant Use (Diagnosis), Hiv
Interventions: Contingency management; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hiv Prevention, Pre-Exposure Prophylaxis (PrEP)
Interventions: Truvada; Drug
Lead sponsor: CAN Community Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Lake Worth, Florida • Miami Beach, Florida + 2 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 13
States / cities: San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more

Conditions: HIV
Interventions: Upper endoscopy, Anoscopy, Truvada; Procedure · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV-1
Interventions: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 16
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more

Search by objective public record fields.

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

Sleep and Cognition After Atripla to Stribild Switch

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

Rapid HIV Treatment Initiation, Access and Engagement in Care

Contingency Management in HIV Care for Both Stimulant Use & ART Adherence

PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP)

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care